Robert Duggan, biotech entrepreneur and investor, built his fortune by identifying overlooked medical assets and scaling them into blockbuster businesses. He is best known for leading Pharmacyclics as CEO and majority owner, turning the company into a major oncology success through the development of Imbruvica, before selling it to AbbVie in a multibillion-dollar deal. Known for bold conviction, aggressive capital deployment, and a willingness to bet heavily on scientific outcomes, Duggan has become one of the most successful dealmakers in modern biotechnology.

Randal J. Kirk, biotech entrepreneur and investor, built his fortune by creating and scaling life-sciences companies focused on drug development, specialty pharmaceuticals, and healthcare innovation. Best known as the founder of Intrexon and as the driving force behind multiple public biotech ventures, Kirk has pursued an aggressive strategy of acquiring scientific platforms, recruiting top research talent, and commercializing high-value therapies. His long-term influence spans pharmaceuticals, genetics, and medical technology, reflecting a rare ability to combine capital markets skill with scientific ambition.

Pablo Legorreta, founder and CEO of Royalty Pharma, built a category-defining firm by pioneering royalty-based investing in biopharmaceutical innovation. After founding the company in 1996, Legorreta created a model that provides non-dilutive capital to drug developers in exchange for royalty streams on approved medicines, helping finance breakthroughs while managing risk through diversified cash flows. Under his leadership, Royalty Pharma scaled into a multibillion-dollar, publicly traded platform that partners with leading biotech companies and academic institutions worldwide, reshaping how life-science innovation is funded.

Noubar Afeyan, founder and CEO of Flagship Pioneering, is a leading biotech entrepreneur and venture creator known for inventing companies at the intersection of science and breakthrough innovation. Through Flagship, he has co-founded and incubated dozens of life-sciences companies, most notably Moderna, helping pioneer the mRNA platform that reshaped vaccine development and global public health. Trained as a chemical engineer, Afeyan combines deep scientific rigor with venture discipline, backing long-horizon technologies across biology, health, and sustainability. His work has made Flagship a cornerstone of modern biotech company creation.

Julian Baker, cofounder of Baker Bros. Advisors, is one of the most successful investors in the biotechnology industry, building a multibillion-dollar hedge fund focused on high-conviction positions in drug development and life sciences. Together with his brother Felix, he has backed breakthrough therapeutics and major biotech companies including Seagen, Incyte, and Alexion, often taking large, long-term positions and working closely with management teams. Known for rigorous scientific analysis, patience, and a deep understanding of clinical risk, Baker has become a central figure in biotech capital markets, influencing the trajectory of drug innovation while maintaining one of the top track records in the sector.

Felix Baker is a highly influential biotech-focused investor and co-founder of Baker Brothers Advisors, a leading hedge fund specializing in healthcare and biotechnology investing. Through his firm, established in 2000, Felix manages over $20 billion in assets and helped generate an estimated $8 billion gain from early investments in Seagen. A PhD immunologist and Stanford alumnus, he also serves on boards of key biotech companies and contributes to Stanford’s biosciences initiatives.